Disease · EFO_0008559

American trypanosomiasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. American trypanosomiasis. Diseases, record EFO_0008559. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008559

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: American trypanosomiasis; Open Targets
Open Targets ID: EFO_0008559; Open Targets
Other names: Chagas disease, South American trypanosomiasis, Trypanosoma cruzi Infection, Trypanosoma cruzi caused disease or disorder, Trypanosoma cruzi disease or disorder, Trypanosoma cruzi infectious disease, human American trypanosomiasis, infection by trypanosoma cruzi; Open Targets
Disease Ontology: DOID:12140; Disease Ontology
MeSH: D014355; MeSH
NCI Thesaurus: C84629; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 7 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BENZNIDAZOLE	CHEMBL110	Small molecule	Approval	DailyMed, FDA and TTD	20	17	17	Drugs and targets
NIFURTIMOX	CHEMBL290960	Small molecule	Approval	DailyMed, FDA and TTD	13	10	10	Drugs and targets
FEXINIDAZOLE	CHEMBL1631694	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
POSACONAZOLE	CHEMBL1397	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FOSRAVUCONAZOLE	CHEMBL333325	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02625974	A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi	Phase 3	330	2019-10-29	Chagas Disease	NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT01377480	A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)	Phase 2	120	2015-08-10	Chagas Disease	BENZNIDAZOLE, POSACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03784391	Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina		3,000		Chagas' Disease	NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT02386358	Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial	Phase 3	910		Chagas Disease	BENZNIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02369978	CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)	Phase 2/3	500		Chagas Disease	BENZNIDAZOLE, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT03981523	New Therapies and Biomarkers for Chagas Infection	Phase 2	450		Trypanosoma Cruzi Infection, Chagas Disease	BENZNIDAZOLE, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT04897516	Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease	Phase 3	300		Chagas Disease	BENZNIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04984616	Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease	Phase 2	300		Chronic Chagas Disease	ATORVASTATIN, BENZNIDAZOLE, NIFURTIMOX	Its record names the disease	ClinicalTrials.gov
NCT03191162	Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.	Phase 2	238		Chagas Disease, Trypanosoma Cruzi Infection	BENZNIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01489228	Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease	Phase 2	230		Chronic Chagas Disease, Indeterminate	BENZNIDAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)	0 of 219	0 of 111	330	NCT02625974	Trial comparisons
Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators	0 of 219	0 of 111	330	NCT02625974	Trial comparisons
Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1	2 of 219	0 of 111	330	NCT02625974	Trial comparisons
Nifurtimox 60-day Regimen vs Nifurtimox 30-day Regimen: deaths from any cause	0 of 219	0 of 111	330	NCT02625974	Trial comparisons
Nifurtimox 60-day Regimen vs Nifurtimox 30-day Regimen: serious adverse events	6 of 219	3 of 111	330	NCT02625974	Trial comparisons
Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10	1 of 212	0 of 109	321	NCT02625974	Trial comparisons
Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9	1 of 213	0 of 107	320	NCT02625974	Trial comparisons
Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11	3 of 210	3 of 108	318	NCT02625974	Trial comparisons

Papers from its trials36

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33412557	RESULT	1	PubMed
28231946	RESULT	1	PubMed
24867876	RESULT	1	PubMed
21264349	RESULT	1	PubMed
16702588	RESULT	1	PubMed
16235350	RESULT	1	PubMed
9790423	RESULT	2	PubMed
8948328	RESULT	1	PubMed
8937280	RESULT	2	PubMed
8273735	RESULT	1	PubMed

1 to 10 of 36

See all 36 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0008559

GET https://conductscience.org/api/diseases/v1/EFO_0008559/trials?page=2

API reference For AI assistants